Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson’s disease

6 Apr 2017

Abstract excerpt

BACKGROUND. We report the 12-month clinical and imaging data on the effects of bilateral delivery of the glutamic acid decarboxylase gene into the subthalamic nuclei (STN) of advanced Parkinson’s disease (PD) patients. METHODS. 45 PD patients were enrolled in a 6-month double-blind randomized trial of bilateral AAV2- GAD delivery into the STN compared with sham surgery and were followed for 12 months in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Nerve injury and regeneration
Share to Neurological disorders and treatments
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28405611
DOI: 10.1172/jci.insight.90133

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson’s diseasePMID 28405611Read ↗

Subthalamic GAD gene therapy in a Parkinson's disease rat model.Semantic proximity Read ↗

Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's DiseaseSemantic proximity Read ↗

A compact glutamic acid decarboxylase 67 promoter enables inhibitory neuron-targeted AAV gene therapy for treatment-resistant epilepsySemantic proximity Read ↗

Gene Therapy for Dopamine Dyshomeostasis: From Parkinson's to Primary Neurotransmitter DiseasesSemantic proximity Read ↗

Optimized AAV capsids for diseases of the basal ganglia show robust potency and distribution in adult nonhuman primatesSemantic proximity Read ↗

Optimized AAV capsids for basal ganglia diseases show robust potency and distributionSemantic proximity Read ↗

Perspective on the Road toward Gene Therapy for Parkinson’s DiseaseSemantic proximity Read ↗

Short-and long-term responsiveness of deep brain stimulation on motor and cognitive outcomes in GBA vs. Non-GBA parkinson's disease: a systematic review and meta-analysis of observational studies.Semantic proximity Read ↗

Administration of barcoded AAV capsid library to the putamen of non-human primates identifies variants with efficient retrograde transportSemantic proximity Read ↗

Gene Therapy for Aromatic L-Amino Acid Decarboxylase Deficiency by MR-Guided Direct Delivery of AAV2-AADC to Midbrain Dopaminergic NeuronsSemantic proximity Read ↗

Altered glutamate signaling in Parkinson’s disease patients with REM sleep behavior disorderSemantic proximity Read ↗

New MiniPromoter Ple389 (ADORA2A) Drives Selective Expression in Medium Spiny Neurons in Mice and Non-human PrimatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.